Morgan Stanley analyst Tejas Savant maintained a Hold rating on Adaptive Biotechnologies (ADPT – Research Report) yesterday and set a price target of $7.00. Tejas Savant’s rating is based on
Morgan Stanley analyst Tejas Savant maintained a Hold rating on Adaptive Biotechnologies (ADPT – Research Report) yesterday and set a price target of $7.00. Tejas Savant’s rating is based on
Scotiabank analyst Sung Ji Nam maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at
J.P. Morgan analyst Rachel Vatnsdal maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) today and set a price target of $7.00. The company’s shares closed last Friday
Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $7 from $6 following quarterly results. The firm keeps an Overweight rating on the shares. Published first on